Human Trials

Pfizer and Lilly’s tanezumab succeeds in second phase 3 osteoarthritis pain trial

Pfizer and Eli Lilly have announced positive top-line results from a phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain.

Shield Therapeutics’ Feraccru yields positive results in extended phase 3 trial

Shield Therapeutics said that its oral ferric iron therapy Feraccru succeeded in the open-label extension phase of the AEGIS-CKD study held in chronic kidney disease (CKD) patients with iron deficiency anaemia (IDA).

Takeda’s TAK-003 dengue vaccine candidate succeeds in phase 3 efficacy trial

Takeda Pharmaceutical’s investigational live-attenuated tetravalent dengue vaccine (TAK-003) candidate has met the primary endpoint in the pivotal phase 3 efficacy trial.

Alexion unveils positive top-line results from phase 3 study of Ultomiris in aHUS

Alexion Pharmaceuticals announced that the Phase 3 study of ULTOMIRIS (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its primary objective in complement inhibitor-naïve patients with atypical hemolytic uremic syndrome (aHUS).

Destiny’s XF-73 meets primary objective in second phase 1 skin irritation study

Destiny Pharma has reported positive data and non-irritant classification for the nasal gel formulation of its synthetic antimicrobial drug XF-73 in the second phase 1 skin irritation study.

Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression

Navitor Pharmaceuticals announced the initiation of Part B of its Phase 1 clinical study with its lead candidate, NV-5138, for treatment-resistant depression (TRD).

Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463

Ironwood Pharmaceuticals announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders.

Redx gets regulatory nod to restart RXC004 clinical trial

Redx has secured approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to restart a phase 1/2a trial for its cancer candidate RXC004 in advanced solid tumors.

Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism

Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced it has initiated dosing in a Phase 2 study for its lead compound, SXC-2023, for the treatment of moderate to severe trichotillomania in adults.